Atopic Dermatitis | Hoffmann-La Roche | GS29250
Pharmaceutical Company/Sponsor:
Hoffmann-La Roche
Code:
GS29250
Title:
A phase II, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately controlled by topical corticosteroids
Type:
Phase:
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Status:
Completed
Link for Additional Information:
